Entourage AI launches with a little help from its friends

A spin-out company from the University of Glasgow has launched thanks to directed support from GRID and its partners.

Entourage AI, a longevity and healthspan focused data company, has announced a $5 million (£3.75 million) pre-seed raise alongside the opening of its new Research and Operations Centre in Glasgow, Scotland, as well as the preorder launch of its proprietary Aging Clock and Organ Health products.

The funding round was led by Provision, with investment also coming from GU Holdings Ltd, healthtech investors David Peterson and Brad Peltz, and other angel investors.

Investment

The centre comprises access to a suite of new Thermo Fisher Scientific Mass Spectrometry assets, made possible with the investment of partners at the University of Glasgow and Scottish Enterprise through the Glasgow Riverside Innovation District, as well as a research collaboration with Thermo Fisher. 

Entourage AI has been supported by R&D grants from Scottish Enterprise, allowing the rapid development of the aging clock and organ health products.

• Pictured, left to right, Professor Patrick Gunning, Entourage AI CEO, Richard Lochhead, Minister for Business of Scotland and Dr Rupa Nagar, Proteomics Lead Scientist, as she demonstrates use of the Thermo Fisher Scientific Astral Mass Spectrometer. Photo credit: Martin Shields

For years, people have relied on genetic testing or external wearables—like fitness bands, smart rings, and connected scales—to piece together a picture of their health.

But an individual's DNA is merely a blueprint of what could happen, and even the most advanced wristbands only track surface-level physiological outputs like heart rate or sleep. To understand the fundamental causes of what is actually happening inside the human body right now, we need to look at our proteins.

Until recently, analysing human proteins at scale required expensive, room-sized equipment confined to advanced academic research facilities. Now, Entourage AI is changing that narrative.

By analysing thousands of proteins, Entourage AI’s platform provides users with highly personalised insights into their biological age; how fast their body is actually aging compared to their chronological age, alongside detailed maps of individual organ wellness. These insights in turn will determine a set of interventions to avoid or delay a wide range of diseases - from cancers to cardiovascular disease.

Entourage AI’s proprietary solutions will help users assess their biological age and how it compares to their chronological age (Aging Clock), understand which of their organs may benefit the most from health intervention (Organ health) and choose which interventions they could take to slow (or possibly reverse) aging – or take action where needed (AI Coach).

The platform is built on Entourage AI’s proprietary reference model of a healthy proteome, developed from mass spectrometry–based analyses of thousands of individuals aged 16 to 85. Using this dataset, which includes measurements of human proteins and millions of peptides, the system estimates biological age and provides organ-specific health insights.

Our mission at Entourage AI is to transform how we measure and understand human health. By harnessing advanced proteomics and AI, we can move beyond reactive medicine toward earlier detection, more precise insights, and truly personalised care.

Professor T. Gunning

Preorders are available now to consumers in UK and USA, as well as to research institutions, longevity clinics, health systems, and enterprise partners. Early participants will receive priority access to testing cohorts, collaborative research programs, API integration, and deployment options.

The company’s Research and Operations Centre is located in Glasgow’s West of Scotland Science Park. With a new Glasgow-based research centre and a breakthrough in scaling proteomic analysis for everyday use, Entourage AI brings the future of preventative medicine into the present, opening the door to earlier detection, personalised interventions, and a radically more informed approach to longevity.

With the ultimate ambition of seeing the technology commonly integrated into the NHS and other global health care providers, Entourage AI will continue to drive technological refinement. 

Entourage AI was founded and is led by serial entrepreneur Patrick T. Gunning, a Professor at the University of Glasgow, who serves as CEO.  Speaking about the company’s vision, Professor Gunning said: “Our mission at Entourage AI is to transform how we measure and understand human health. By harnessing advanced proteomics and AI, we can move beyond reactive medicine toward earlier detection, more precise insights, and truly personalised care.”

Scottish Business Minister Richard Lochhead said: “Scotland has a rich history for innovation and invention and now Scottish companies and institutions are pioneering many of the developments that are rapidly re-shaping the world. The technology being developed by Entourage AI illustrates how artificial intelligence can be used to transform healthcare - both here and across the world.

“As a Scottish-rooted spinout from the University of Glasgow, I am delighted that Entourage AI has secured such a significant raise and wish the company every success as it moves into its new research and operations centre and begins taking orders across its latest products."

Expansion

Executive Chair Gerard Cunningham, a Silicon Valley-based, serial AI founder with two unicorn exits, is leading the company’s expansion into US markets, and developing a network of strategic partnerships.

Spin-outs formed at the University of Glasgow since 2020 have collectively secured over £130 million in investment, now employing more than 300 people and demonstrating the growing strength of the University’s innovation pipeline.

The Entourage story represents an inspirational exemplar of the innovation and commercial growth happening within the Glasgow Riverside Innovation District (GRID).